Outlook Therapeutics names Kevin Lundquist as new CFO
Lawrence Kenyon steps down as CFO effective September 1, 2026, with Kevin Lundquist taking over the role and other financial officer duties.
SEC filing
Latest
7 stories
Thursday, August 27
Friday, August 14
Outlook Therapeutics prices $55 million stock and warrant offering
The company plans to use proceeds along with existing cash to launch LYTENAVA in the US, where it holds a going concern warning and about $11.2 million in cash as of June 30, 2026.
SEC filing (2)
Outlook Therapeutics details LYTENAVA US launch prep in Q3 FY2026 update
The company said it is readying a U.S. launch of FDA-approved wet AMD drug LYTENAVA by year-end 2026, reporting $11.2 million in cash plus a subsequent $51.1 million offering.
SEC filing (2)
Monday, August 3
Outlook Therapeutics posts Phase 3 results for ONS-5010 in wet AMD trial
Friday, July 24
Outlook Therapeutics wins FDA approval for Lytenava in wet AMD
The July 24, 2026 approval makes Lytenava the first FDA-approved ophthalmic bevacizumab for wet age-related macular degeneration, with launch expected before year-end.
SEC filing
Thursday, July 23
Outlook Therapeutics grants options and bonuses tied to ONS-5010 BLA progress
The company's compensation committee approved stock options for its CEO and CFO and cash bonuses contingent on FDA approval of ONS-5010 by July 31, 2026.
SEC filing